Baidu
map

Cell Rep:小颅畸形症致病机制研究获进展

2014-01-21 中国科学报 中国科学报

日前,中科院遗传与发育生物学研究所研究人员在WDR62在大脑发育过程中的功能和相关机制研究方面获进展,相关成果日前发表于《细胞》子刊《细胞报告》。 WDR62基因突变被认为与小颅畸形症和智力低下密切相关。同时,WDR62基因突变已被公认为造成小颅畸形症的第二大主因。但是,目前学界对有关WDR62的大脑发育过程中的功能和作用机制,以及WDR62突变如何导致小颅畸形症的致病机制尚不清楚。 小颅畸形

日前,中科院遗传与发育生物学研究所研究人员在WDR62在大脑发育过程中的功能和相关机制研究方面获进展,相关成果日前发表于《细胞》子刊《细胞报告》。

WDR62基因突变被认为与小颅畸形症和智力低下密切相关。同时,WDR62基因突变已被公认为造成小颅畸形症的第二大主因。但是,目前学界对有关WDR62的大脑发育过程中的功能和作用机制,以及WDR62突变如何导致小颅畸形症的致病机制尚不清楚。

小颅畸形症是一种原发性小头畸形,患者个体出生时表现为头围小和智力障碍,而无其他神经生物学异常。经过研究,遗传与发育生物学研究所许执恒课题组发现,WDR62调控JNK信号通路并位于JNK1上游,WDR62通过调控JNK1的活性参与脑发育过程中神经干细胞发育。进一步研究表明,WDR62和JNK1通过调控神经干细胞中纺锤体的形成来影响神经干细胞的自我更新与对称性分裂。

原文出处:

Dan Xu, Feng Zhang, Yaqing Wang, Yiming Sun, Zhiheng Xu.Microcephaly-Associated Protein WDR62 Regulates Neurogenesis through JNK1 in the Developing Neocortex.Cell Reports 2014 Jan 16 doi:10.1016/j.celrep.2013.12.016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868759, encodeId=b4c41868e59c7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 10 05:09:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959000, encodeId=1b8f195900092, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 21 06:09:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056122, encodeId=9e172056122d3, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 00:09:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801210, encodeId=3050180121028, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 11 04:09:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921011, encodeId=1880192101123, content=<a href='/topic/show?id=480486482e5' target=_blank style='color:#2F92EE;'>#致病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86482, encryptionId=480486482e5, topicName=致病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Oct 18 10:09:00 CST 2014, time=2014-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362103, encodeId=818c1362103c6, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 23 06:09:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868759, encodeId=b4c41868e59c7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 10 05:09:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959000, encodeId=1b8f195900092, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 21 06:09:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056122, encodeId=9e172056122d3, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 00:09:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801210, encodeId=3050180121028, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 11 04:09:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921011, encodeId=1880192101123, content=<a href='/topic/show?id=480486482e5' target=_blank style='color:#2F92EE;'>#致病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86482, encryptionId=480486482e5, topicName=致病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Oct 18 10:09:00 CST 2014, time=2014-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362103, encodeId=818c1362103c6, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 23 06:09:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
    2014-08-21 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868759, encodeId=b4c41868e59c7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 10 05:09:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959000, encodeId=1b8f195900092, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 21 06:09:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056122, encodeId=9e172056122d3, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 00:09:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801210, encodeId=3050180121028, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 11 04:09:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921011, encodeId=1880192101123, content=<a href='/topic/show?id=480486482e5' target=_blank style='color:#2F92EE;'>#致病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86482, encryptionId=480486482e5, topicName=致病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Oct 18 10:09:00 CST 2014, time=2014-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362103, encodeId=818c1362103c6, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 23 06:09:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868759, encodeId=b4c41868e59c7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 10 05:09:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959000, encodeId=1b8f195900092, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 21 06:09:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056122, encodeId=9e172056122d3, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 00:09:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801210, encodeId=3050180121028, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 11 04:09:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921011, encodeId=1880192101123, content=<a href='/topic/show?id=480486482e5' target=_blank style='color:#2F92EE;'>#致病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86482, encryptionId=480486482e5, topicName=致病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Oct 18 10:09:00 CST 2014, time=2014-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362103, encodeId=818c1362103c6, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 23 06:09:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1868759, encodeId=b4c41868e59c7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 10 05:09:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959000, encodeId=1b8f195900092, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 21 06:09:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056122, encodeId=9e172056122d3, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 00:09:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801210, encodeId=3050180121028, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 11 04:09:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921011, encodeId=1880192101123, content=<a href='/topic/show?id=480486482e5' target=_blank style='color:#2F92EE;'>#致病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86482, encryptionId=480486482e5, topicName=致病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Oct 18 10:09:00 CST 2014, time=2014-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362103, encodeId=818c1362103c6, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 23 06:09:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1868759, encodeId=b4c41868e59c7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 10 05:09:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959000, encodeId=1b8f195900092, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 21 06:09:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056122, encodeId=9e172056122d3, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Dec 31 00:09:00 CST 2014, time=2014-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801210, encodeId=3050180121028, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Mar 11 04:09:00 CST 2014, time=2014-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921011, encodeId=1880192101123, content=<a href='/topic/show?id=480486482e5' target=_blank style='color:#2F92EE;'>#致病机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86482, encryptionId=480486482e5, topicName=致病机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Oct 18 10:09:00 CST 2014, time=2014-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362103, encodeId=818c1362103c6, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 23 06:09:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]

相关资讯

**肿瘤分子诊断平台建成

从日前在天津市召开的基因检测技术在肿瘤个体化诊疗中的应用学术研讨会上获悉,国家肿瘤临床医学研究中心肿瘤分子诊断平台已建成,作为该平台的重要组成部分,乳腺癌高危人群基因筛选技术以及肺癌基因检测技术已在临床投入使用。 肿瘤分子诊断平台旨在探索标准化的肿瘤分子诊断规范,为制订个体化防治方案提供分子水平依据。该平台由天津市肿瘤医院肿瘤分子诊断中心负责运作。该院肿瘤分子诊断中心

Nat Mater:新纳米成像系统可检测更多类型肿瘤

近日的《自然—材料学》报道了一种新的纳米粒子成像系统可以扫描到更多类型的肿瘤。【原文下载】 癌症有很多种基因型和表现型,因而找到一种能够应用范围广的成像方法颇具挑战性。但是,肿瘤微环境中还是存在一些共同的因素可以被用于检测,比如高酸度以及快速血管生长。 Jinming Gao等人在报告中描述了一类pH超灵敏的荧光纳米粒子,这类粒子能够针对很多患有不同癌症的小鼠体内的肿瘤微环境中的酸度和血管发育

Nat Genet:发现难治性肿瘤的可靶向突变

由麻省总医院(MGH)、Brigham妇女医院(BWH)和Broad研究所领导的一个研究小组,发现与几个癌症类型相关的一种基因突变有可能也导致了另一种罕见的脑瘤:乳头型颅咽管瘤(papillary craniopharyngioma)。他们的研究发现有可能促成新疗法来对抗这种目前难以治疗的肿瘤,相关论文在线发表在《自然遗传学》(Nature Genetics)杂志上。

Nature子刊:肿瘤相关突变之间的竞争行为

组织干细胞(Tissue stem cell)可能是多种肿瘤的始动原因,不过这些细胞里致癌的“司机突变(driver mutation)”在生理条件下的下游效应因子现在还不是十分清楚。不过两个最新的干细胞体内研究发现了好几个效应因子。Li等人使用了一种经过人工遗传学改造的小鼠做动物模型进行了研究,这种试验小鼠的造血系统可以在人工诱导的条件下表达一种Cre重组酶,该重组酶能够激活NrasG12D等位

Science:利用RNAi揭示与癌症发展相关的未知基因

近日,发表在Science杂志上的一篇研究论文中,科学家们发现某些基因缺失与肿瘤生长之间的一种前所未知的联系。研究小组利用RNAi,发现以前未知的遗传基因缺失与癌变肿瘤的相关性。 Fig. 1 Direct in vivo shRNA screen for HNSCC tumor suppressors 在过去的几年里,科学家已经了解到,基因在癌症发展中产生了比人们以前认为的更大的作用。在这项

Circ Res:阻断整合素β3只能暂时抑制肿瘤

      根据东安格利亚大学(UEA)的一项最新研究,在过去20年里一直被视为癌症药物设计中心的一种蛋白——整合素β 3( β3-integrin),不应该被放弃用于治疗。         在治疗恶性脑肿瘤的临床试验中,最先进版本的整合素β3拮抗剂的

Baidu
map
Baidu
map
Baidu
map